NCT05344989View on ClinicalTrials.gov

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

July 31, 2024

Conditions
Healthy VolunteersTauopathiesAlzheimer Disease
Interventions
DRUG

APNmAb005

Administered by IV infusion

DRUG

Placebo

Administered by IV infusion

Trial Locations (1)

90806

Collaborative Neuroscience Research, LLC., 2600 Redondo Ave., Long Beach

Sponsors
All Listed Sponsors
lead

APRINOIA Therapeutics, LLC

INDUSTRY